SMRTR summary
AI is revolutionizing drug discovery, potentially reducing development time and costs. At least 75 AI-discovered molecules have entered clinical trials, with companies like Insilico Medicine and Recursion Pharmaceuticals showing promising results in treating rare diseases and cancer using AI-driven approaches.
SMRTR provides this summary for quick context. The original article belongs to BBC News.
Read the original articleThis archive is built from SMRTR newsletter stories. Subscribe for hand-picked stories without the extra noise.
Expert Sniper is an open-source tool that pools storage and memory across multiple Macs to run large AI models. A 17GB model can run on a Mac with just 3.6GB RAM, achieving 19.3...
PI Agent outperformed OpenCode with faster speeds, better token efficiency, and higher context retention (90k vs. 67k). After minor tuning, it nearly matched and slightly...
vLLM-iOS is a native Swift port of vLLM for iPhones, delivering 88% faster multi-agent inference than llama.cpp by sharing weight reads and reusing cached prefixes—running 16...
AI chatbots can improve fake news detection by 21%, but prolonged use may reduce independent judgment by 15%. Question-based chatbots better develop critical thinking skills,...
Tech companies are exploring underwater and floating data centers in Asia that use seawater for cooling, reducing electricity use by up to 30%. Concerns remain over marine heat...
IBM released Granite 4.2, a reasoning-focused LLM family in 3B, 8B, and 30B sizes, pre-trained on 15T tokens and refined with RL. The 8B and 30B models support tool use, code...